drugset / Trial / NCT01533116

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

NCT01533116

Phase 1 Completed 52 enrolled Bial - Portela C S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics

Timeline

Start
2009-03
Primary completion
2009-08
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 5 mg
Subject Opicapone Small molecule 15 mg
Subject Opicapone Small molecule 30 mg
Subject levodopa/benserazide Unknown
Subject levodopa/carbidopa Unknown

Indications